Skip to main content
. 2017 Feb 1;113(6):633–643. doi: 10.1093/cvr/cvx016

Figure 2.

Figure 2

OPN aptamer reduces gene expression of extracellular matrix and heart failure genes and inhibits OPN signalling pathway in left ventricles (LVs). (A) Changes of mRNA expression as measured by qPCR at 4 and 12 weeks post-TAC after systemic injections of OPN aptamer (Apt) or mutant OPN aptamer (M-Apt). (B and C) Changes of protein expression as measured by western blot and corresponding quantification, or Elisa—at 4 weeks post-TAC after systemic injections of OPN aptamer or mutant OPN aptamer. Error bars = SEM. P-values are from ANOVA with Tukey multiple correction. *P ≤0.05 vs. Sham; **P ≤ 0.01 vs. Sham; †P ≤ 0.05 vs. TAC + M-Apt; ††P ≤ 0.01 vs. TAC + M-Apt. n = 5–7 mice per group. Nppa, Natriuretic Peptide A; Nppb, Natriuretic Peptide B; OPN, Osteopontin; FN1, Fibronectin 1, Col III, pro-alpha1 (III) collagen; Lum, Lumican; n.d.u.= normalized densitometry units; TAC, Transverse Aortic Constriction.